Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

FORGOTTEN HISTORY: T2 biosystems secures additional barda funding to develop blood test panels to detect sepsis causing pathogens - Caught on Camera

  • The Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems Inc (NASDAQ:TTOO
  • If all contract options are exercised, the total potential BARDA funding is $69.0 million.
  • The additional funding will be used to advance the U.S. clinical trials for the T2Biothreat Panel & T2Resistance Panel and develop the Company's comprehensive panel to detect bloodstream infections and antimicrobial resistance.
  • T2Biothreat Panel: Direct-from-blood test panel to simultaneously detect six biothreat pathogens.
  • T2Resistance Panel: Direct-from-blood test panel to simultaneously detect thirteen antibiotic resistance genes from Gram-positive and Gram-negative bacterial pathogens.
  • A comprehensive panel is designed to detect greater than 95% of all bloodstream infections caused by bacterial and Candida pathogens and antibiotic resistance markers in a single test with a time to result of approximately 3 hours.
  • The Company initiated U.S. trials for both the T2Biothreat Panel and T2Resistance Panel in December 2021, enabling the potential filing of FDA submissions for both products during 2022.
  • Price Action: TTOO shares are up 7.71% at $0.56 during the market session on the last check Friday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.